Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.71987 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, online erschienen am 27.05.2026. Verfasst von Zejian Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Male, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical research project of the First Affiliated Hospital of Xi'an Jiaotong University, Innovation Capability Support Program of Shaanxi.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The survival benefit of neoadjuvant chemotherapy (Neo‐CT) among male breast carcinoma (MaBC) remains unclear, and the specific population that can benefit from Neo‐CT is also not yet defined. We utilized the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database and employed Kaplan–Meier analysis; Cox proportional hazards model and binary variable Logistic regression were performed to evaluate the effect of Neo‐CT on the therapeutic response and prognosis of MaBC patients. Among the 4171 MaBC subjects included, 194 (4.7%) patients received Neo‐CT only (Neo‐CT only group), 246 (5.9%) cases received adjuvant chemotherapy and Neo‐CT (CT + Neo‐CT group); the remaining 3731 (89.5%) cases received postoperative chemotherapy only (CT‐only group). Totally, 20 (12.12%) participants achieved pathological complete response (pCR). And patients who achieved a pCR (pCR subgroup) had improved 5‐year and 10‐year overall survival (OS) (100.0% vs. 79.70% vs. 73.81%, 100.0% vs. 59.12% vs. 28.82%, respectively) and breast cancer‐specific survival (BCSS) (86.30% vs. 91.49%, 69.04% vs. 83.32%, respectively) in comparison with those in the Non‐pCR subgroup. Further binary Logistic regression analysis showed that the achievement of pCR might be related to stage I‐II ( p = 0.007) and hormone receptor (HR) negative ( p = 0.010) disease, and the pCR rate of stage I‐II and HR− MaBC patients was 66.67%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- School of Medicine, Xi'an Jiaotong University, Xi'an, China.
- Department of Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Förderung
- Clinical research project of the First Affiliated Hospital of Xi'an Jiaotong University
- Innovation Capability Support Program of Shaanxi
Zitieren
APA
Yang, Z., Ni, P., Wang, Y., Wang, R., Wang, B., Ren, Y., Ge, G., Liu, F., He, J., & Zhou, C. (2026). Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.71987
Vancouver
Yang Z, Ni P, Wang Y, Wang R, Wang B, Ren Y, et al. Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.71987
BibTeX
@article{Yang2026,
author = {Yang, Zejian and Ni, Peng and Wang, Yu and Wang, Ruixin and Wang, Bo and Ren, Yu and Ge, Guanqun and Liu, Fan and He, Jianjun and Zhou, Can},
title = {Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.71987}
}
EUVIMED